JP6450769B2 - グルコピラノシル誘導体及びその医薬品における使用 - Google Patents

グルコピラノシル誘導体及びその医薬品における使用 Download PDF

Info

Publication number
JP6450769B2
JP6450769B2 JP2016544709A JP2016544709A JP6450769B2 JP 6450769 B2 JP6450769 B2 JP 6450769B2 JP 2016544709 A JP2016544709 A JP 2016544709A JP 2016544709 A JP2016544709 A JP 2016544709A JP 6450769 B2 JP6450769 B2 JP 6450769B2
Authority
JP
Japan
Prior art keywords
phenyl
mmol
methyl
chloro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016544709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535074A (ja
JP2016535074A5 (https=
Inventor
ウェイ、ヨンガン
ウェン、ジアピン
チュウ、グオツィ
ル、ヨンハ
ワン、ヘエラン
ワン、インカイ
ユアン、ミンギュン
グ、ツェン
ウ、ウヨン
カン、パンパン
ツァン、ゾンヤン
チェン、ガン
タン、ペンホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2016535074A publication Critical patent/JP2016535074A/ja
Publication of JP2016535074A5 publication Critical patent/JP2016535074A5/ja
Application granted granted Critical
Publication of JP6450769B2 publication Critical patent/JP6450769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2016544709A 2013-09-27 2014-09-26 グルコピラノシル誘導体及びその医薬品における使用 Active JP6450769B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310450401 2013-09-27
CN201310450401.2 2013-09-27
PCT/CN2014/087587 WO2015043511A1 (en) 2013-09-27 2014-09-26 Glucopyranosyl derivatives and their uses in medicine

Publications (3)

Publication Number Publication Date
JP2016535074A JP2016535074A (ja) 2016-11-10
JP2016535074A5 JP2016535074A5 (https=) 2017-11-02
JP6450769B2 true JP6450769B2 (ja) 2019-01-09

Family

ID=52742084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544709A Active JP6450769B2 (ja) 2013-09-27 2014-09-26 グルコピラノシル誘導体及びその医薬品における使用

Country Status (7)

Country Link
US (1) US9394329B2 (https=)
EP (1) EP2895490B1 (https=)
JP (1) JP6450769B2 (https=)
CN (1) CN104513283B (https=)
CA (1) CA2889699C (https=)
ES (1) ES2605886T3 (https=)
WO (1) WO2015043511A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016173425A1 (en) * 2015-04-30 2016-11-03 Sunshine Lake Pharma Co., Ltd. A glucopyranosyl derivative and preparation method and uses thereof
CN106674294B (zh) * 2015-11-06 2020-07-07 广东东阳光药业有限公司 吡喃葡萄糖基衍生物的结晶形式
CA3005920C (en) 2015-11-27 2023-08-22 Sunshine Lake Pharma Co., Ltd. A complex of a glucopyranosyl derivative and preparation method and use thereof
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
US10519183B2 (en) * 2016-05-04 2019-12-31 Youngene Therapeutics Co., Ltd. Amine solvate of sodium-glucose linked transporter inhibitor, and preparation method and application thereof
CN107778336B (zh) * 2016-08-24 2022-09-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的结晶形式
CN106674245B (zh) * 2017-01-10 2019-07-26 北京中海康医药科技发展有限公司 吡喃葡萄糖基衍生物的制备及医药上的应用
JP2019001746A (ja) * 2017-06-15 2019-01-10 株式会社クラレ ジオールの製造方法
CN107986972A (zh) * 2017-11-10 2018-05-04 潍坊润安化学科技有限公司 一种3-(4-硝基苯氧基)丙酸制备方法
EP4178970A4 (en) * 2020-07-08 2024-08-07 Sunshine Lake Pharma Co., Ltd. Method for preparing glucopyranosyl derivatives and intermediates thereof
CN114796250A (zh) * 2021-01-27 2022-07-29 宜昌东阳光长江药业股份有限公司 一种含有吡喃葡萄糖基衍生物的药物组合物
WO2022204907A1 (en) * 2021-03-30 2022-10-06 Sunshine Lake Pharma Co., Ltd. Method for preparing cocrystal of l-pyroglutamic acid and glucopyranosyl derivative
CN114835563B (zh) * 2022-05-23 2024-04-26 浙江中欣氟材股份有限公司 一种4,4`-二氟二苯甲酮的合成方法
WO2024012568A1 (en) * 2022-07-15 2024-01-18 Sunshine Lake Pharma Co., Ltd. A key intermediate for preparing glucopyranosyl derivatives and preparation method thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CN1950389B (zh) * 2004-03-04 2011-01-19 橘生药品工业株式会社 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
DE102004012676A1 (de) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE445608T1 (de) 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ES2346347T3 (es) 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2664095A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
AU2008279424B2 (en) 2007-07-26 2013-06-13 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
MX2010002027A (es) 2007-08-23 2010-03-15 Theracos Inc Derivados de bencilbenceno y metodos de uso.
AR070701A1 (es) 2008-02-13 2010-04-28 Sanofi Aventis Derivados de fluoroglicosidos aromaticos, medicamentos que comprenden estos compuestos y uso de los mismos para producir un medicamento
MY155418A (en) * 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010031820A1 (en) 2008-09-19 2010-03-25 Novartis Ag Glucoside derivatives and uses thereof as sglt inhibitors
EA201100502A1 (ru) 2008-09-19 2011-10-31 Новартис Аг Гликозидные производные и их применения
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
WO2011048148A2 (en) 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
CN102134226B (zh) 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2012003811A1 (en) 2010-07-09 2012-01-12 Zhejiang Beta Pharma Inc. C-aryl glucoside sglt2 inhibitors and method
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
JP2013224263A (ja) 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd ４−イソプロピルフェニルグルシトール化合物
EP2607360B1 (en) 2010-08-20 2015-08-19 Taisho Pharmaceutical Co., Ltd. 4-Isopropyl-6-methoxyphenyl glucitol compound
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
CN102643256B (zh) 2011-02-18 2014-12-24 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
CN102675378A (zh) 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
KR20140019834A (ko) 2011-04-14 2014-02-17 노파르티스 아게 글리코시드 유도체 및 그의 용도
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
KR101609859B1 (ko) 2011-04-25 2016-04-07 베이징 프릴루드 팜. 에스씨아이. & 테크. 씨오., 엘티디. 소듐-의존적 포도당 운반 단백질의 억제제 및 이의 제조방법 및 용도
WO2012172566A2 (en) * 2011-06-13 2012-12-20 Panacea Biotec Ltd. Novel sglt inhibitors
US9562029B2 (en) 2011-06-25 2017-02-07 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
CN102408459B (zh) 2011-09-29 2014-07-23 天津药物研究院 一类含异头位烷基的苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2013090550A1 (en) 2011-12-15 2013-06-20 National Health Research Institutes Novel glycoside compounds
WO2013178064A1 (zh) 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
CN103570657A (zh) 2012-07-19 2014-02-12 天津药物研究院 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途
CN103772449B (zh) 2012-10-26 2017-12-26 上海阳帆医药科技有限公司 C‑芳基葡萄糖苷衍生物及其制备方法与用途
EP2933250B1 (en) 2012-12-17 2017-08-09 Tianjin Institute Of Pharmaceutical Research Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
EP2968258B1 (en) 2013-03-11 2020-02-12 Janssen Pharmaceutica NV Dual sglt1/sglt2 inhibitors
CN104059042B (zh) 2013-03-22 2017-02-08 正大天晴药业集团股份有限公司 C-三芳基葡萄糖苷类sglt-2抑制剂
CN104619713B (zh) 2013-05-24 2017-06-16 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2014206349A1 (zh) 2013-06-28 2014-12-31 四川海思科制药有限公司 氧杂-硫杂-双环[3.2.1]辛烷衍生物、制备方法及其用途
WO2015027963A1 (zh) 2013-09-02 2015-03-05 四川海思科制药有限公司 芳环类衍生物、其药物组合物及其应用
CN107311992B (zh) 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物

Also Published As

Publication number Publication date
EP2895490A4 (en) 2015-10-28
US9394329B2 (en) 2016-07-19
HK1207075A1 (en) 2016-01-22
CN104513283A (zh) 2015-04-15
EP2895490A1 (en) 2015-07-22
JP2016535074A (ja) 2016-11-10
WO2015043511A1 (en) 2015-04-02
US20150266916A1 (en) 2015-09-24
AU2014327928A1 (en) 2015-05-14
CN104513283B (zh) 2018-01-16
CA2889699A1 (en) 2015-04-02
CA2889699C (en) 2017-06-06
EP2895490B1 (en) 2016-10-19
ES2605886T3 (es) 2017-03-16

Similar Documents

Publication Publication Date Title
JP6450769B2 (ja) グルコピラノシル誘導体及びその医薬品における使用
EP4192831B1 (en) Heterocyclic glp-1 agonists
RU2667060C2 (ru) Производные маннозы для лечения бактериальных инфекций
WO2016173425A1 (en) A glucopyranosyl derivative and preparation method and uses thereof
KR102755012B1 (ko) 글루코피라노실 유도체 및 이의 용도
WO2011048112A1 (en) Glycoside derivatives and uses thereof
WO2012019496A1 (zh) C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
JP6373352B2 (ja) 細菌感染を処置するためのマンノース誘導体
CN106892948B (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN105461762A (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
EP2865666B1 (en) Hexahydropentaleno derivatives, preparation method and use in medicine thereof
WO2015043473A1 (en) Glucopyranosyl derivatives and their uses in medicine
KR20240165360A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
AU2014327928B2 (en) Glucopyranosyl derivatives and their uses in medicine
KR20140027449A (ko) 신규한 c-아릴 안사 sglt2 억제제
CN103450214B (zh) 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
HK1207075B (en) Glucopyranosyl derivatives and their uses in medicine
CN108203432B (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN103848806B (zh) 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181210

R150 Certificate of patent or registration of utility model

Ref document number: 6450769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250